Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus adalimumab in children with active juvenile psoriatic arthritis
2023-506026-36-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, single-blind trial in juvenile psoriatic arthritis (JPsA) comparing Risankizumab arm with Adalimumab reference arm (2 arms). Primary endpoint: JIA-ACR 30 response at Week 24. Planned start Apr 2024; status: authorised.
02
Drugs
risankizumabadalimumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-506026-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506026-36-00.